141 related articles for article (PubMed ID: 14687037)
1. The value of alloantibody detection in predicting response to HLA-matched platelet transfusions.
Levin MD; Kappers-Klunne M; Sintnicolaas K; van der Holt B; van Vliet HH; Löwenberg B; van't Veer MB
Br J Haematol; 2004 Jan; 124(2):244-50. PubMed ID: 14687037
[TBL] [Abstract][Full Text] [Related]
2. HLA-matched platelet transfusions are effective only in refractory patients with positive HLA antibody screening.
Kreuger AL; Mäkelburg ABU; Somers JAE; Tomson B; van de Watering LMG; van der Bom JG; van Kraaij MGJ; Weller CM
Transfusion; 2019 Nov; 59(11):3303-3307. PubMed ID: 31602653
[TBL] [Abstract][Full Text] [Related]
3. A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions.
Sintnicolaas K; Löwenberg B
Br J Haematol; 1996 Mar; 92(4):1005-10. PubMed ID: 8616059
[TBL] [Abstract][Full Text] [Related]
4. Platelet crossmatching. A direct approach to the selection of platelet transfusions for the alloimmunized thrombocytopenic patient.
Kickler TS; Ness PM; Braine HG
Am J Clin Pathol; 1988 Jul; 90(1):69-72. PubMed ID: 3389345
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of platelet transfusion refractoriness: the use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia.
Kekomäki S; Volin L; Koistinen P; Koivunen E; Koskimies S; Ruutu T; Timonen T; Kekomäki R
Eur J Haematol; 1998 Feb; 60(2):112-8. PubMed ID: 9508352
[TBL] [Abstract][Full Text] [Related]
6. Impact of Human Leucocyte Antigen epitope matched platelet transfusions in alloimmunised aplastic anaemia patients.
Kallon D; Navarrete CV; Sage DA; Stanworth S; Mufti GJ; Marsh JCW; Brown CJ
Transfus Med; 2020 Feb; 30(1):23-29. PubMed ID: 31209973
[TBL] [Abstract][Full Text] [Related]
7. HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients.
Nambiar A; Duquesnoy RJ; Adams S; Zhao Y; Oblitas J; Leitman S; Stroncek D; Marincola F
Blood; 2006 Feb; 107(4):1680-7. PubMed ID: 16269623
[TBL] [Abstract][Full Text] [Related]
8. Platelet transfusions: the problem of refractoriness.
Murphy MF; Waters AH
Blood Rev; 1990 Mar; 4(1):16-24. PubMed ID: 2182145
[TBL] [Abstract][Full Text] [Related]
9. Treatment of severe thrombocytopenia in alloimmunized, transfusion-refractory patients.
Ornstein DL; Mortara KL; Smith MB; Ririe DW; Shaughnessy PJ; Bickford DJ; Kissack BL
Mil Med; 2001 Mar; 166(3):269-74. PubMed ID: 11263033
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients.
Messerschmidt GL; Makuch R; Appelbaum F; Ungerleider RS; Abrams R; O'Donnell J; Holohan TV; Fontana J; Wright D; Anagnou NP
Cancer; 1988 Aug; 62(4):795-801. PubMed ID: 3293762
[TBL] [Abstract][Full Text] [Related]
11. Platelet transfusion refractoriness associated with HPA-1a (Pl(A1)) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions.
Pappalardo PA; Secord AR; Quitevis P; Haimowitz MD; Goldfinger D
Transfusion; 2001 Aug; 41(8):984-7. PubMed ID: 11493728
[TBL] [Abstract][Full Text] [Related]
12. Management of bleeding in a multi-transfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets.
Heuer L; Blumenberg D
Blood Coagul Fibrinolysis; 2005 Jun; 16(4):287-90. PubMed ID: 15870549
[TBL] [Abstract][Full Text] [Related]
13. Human leukocyte antigen (HLA)-incompatible mean fluorescence intensity-selected platelet products have corrected count increments similar to HLA antigen-matched platelets.
Karafin MS; Schumacher C; Zhang J; Simpson P; Johnson ST; Pierce KL
Transfusion; 2021 Aug; 61(8):2307-2316. PubMed ID: 34075590
[TBL] [Abstract][Full Text] [Related]
14. A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients.
Freedman J; Gafni A; Garvey MB; Blanchette V
Transfusion; 1989; 29(3):201-7. PubMed ID: 2493693
[TBL] [Abstract][Full Text] [Related]
15. Platelet transfusions to HLA-immunized recipients: how to be or not to be matched.
Rubinstein P
Transfusion; 2010 Nov; 50(11):2292-4. PubMed ID: 21182628
[No Abstract] [Full Text] [Related]
16. Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations.
Daly PA; Schiffer CA; Aisner J; Wiernik PH
JAMA; 1980 Feb; 243(5):435-8. PubMed ID: 7351763
[TBL] [Abstract][Full Text] [Related]
17. Recognition and management of antibodies to human platelet antigens in platelet transfusion-refractory patients.
Vassallo RR
Immunohematology; 2009; 25(3):119-24. PubMed ID: 20406018
[TBL] [Abstract][Full Text] [Related]
18. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients.
Duquesnoy RJ; Filip DJ; Rodey GE; Rimm AA; Aster RH
Am J Hematol; 1977; 2(3):219-26. PubMed ID: 596366
[TBL] [Abstract][Full Text] [Related]
19. Platelet transfusion refractoriness.
Hod E; Schwartz J
Br J Haematol; 2008 Jul; 142(3):348-60. PubMed ID: 18510692
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of HLA virtual cross-matched platelet transfusions for platelet transfusion refractoriness in hematopoietic stem cell transplantation.
Seike K; Fujii N; Asano N; Ohkuma S; Hirata Y; Fujii K; Sando Y; Nakamura M; Naito K; Saeki K; Meguri Y; Asada N; Ennishi D; Nishimori H; Matsuoka KI; Tsubaki K; Otsuka F; Maeda Y
Transfusion; 2020 Mar; 60(3):473-478. PubMed ID: 31970799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
